Korea's National Bio Big Data Project: Advancing Precision Medicine with Macrogen and Illumina

GST Exemption Announced for Cancer Treatment Gene Therapy

AIIMS Develops Affordable CAR-T Cell Therapy for Multiple Myeloma

Sangamo Therapeutics and Astellas Collaborate on Innovative Gene Therapy for Neurological Diseases

FDA Clears IND for Arbor Biotechnologies’ ABO-101 Gene Editing Therapeutic for Primary Hyperoxaluria Type 1

Fortis Healthcare Acquires Stake in Agilus Diagnostics

FDA Approves BRAFTOVI® Combination Regimen as First-Line Treatment for BRAF V600E-Mutant Metastatic Colorectal Cancer

The Role of Big Data in Precision Medicine

Caris Life Sciences Celebrates 1,000+ Precision Medicine Studies, Advancing Cancer Research and Patient Outcomes

OncoHelix and Qualisure Diagnostics Partner to Bring Thyroid GuidePx® Test to Canadian Patients

Gates Foundation Invests $50 Million in Tessera Therapeutics to Advance Gene Therapy for Sickle Cell Disease

FDA Approves Ensartinib (Ensacove) as First-Line Treatment for ALK-Positive NSCLC

Guardant Health and Boehringer Ingelheim Collaborate to Advance Liquid Biopsy CDx for HER2-Targeted Therapy in NSCLC

Cartherics Receives $300K G-Rex Grant to Advance Cancer Cell Therapy Manufacturing

Roche Revolutionizes Mass Spectrometry Diagnostics with Launch of cobas® Mass Spec Solution

Home
/
update
/
details

Philips Secures FDA Approval for Advanced Digital Pathology System

NextEdge Admin

12 Jul 2024

2 min 53 sec

Diagnosing cancer requires a collaborative effort involving a multidisciplinary team, including oncologists, pathologists, radiologists, and geneticists. Philips’ digital pathology solution is designed to streamline this process with whole-slide scanners, an advanced image management system, and robust implementation services, facilitating the transition from analog to fully digital workflows. To date, Philips has successfully assisted over 300 pathology labs in adopting digital pathology, enabling pathologists to save time and enhance collaboration, which leads to high-quality pathology reports.

The latest iteration, Philips IntelliSite Pathology Solution 5.1, has received 510(k) clearance from the U.S. FDA, reinforcing its status as the most widely deployed digital pathology solution for primary diagnosis since its market launch in 2017. This solution supports remote collaboration, boosts productivity, addresses staff shortages, and reduces costs. Its comprehensive design integrates hardware, software, and enterprise-wide connectivity, empowering pathologists to deliver accurate diagnoses and ultimately improve patient outcomes.

By utilizing digital workflows, IntelliSite significantly enhances productivity, reducing case review and reporting time by up to 21% compared to traditional methods. This efficiency is vital in overcoming the chronic shortage of trained pathologists and meeting the growing demand in both commercial and hospital settings. The solution enables remote consultations and incorporates AI applications, facilitating timely precision diagnoses and ensuring secure data access throughout the patient's care journey.

Philips’ open-platform approach further supports the integration of third-party AI applications, which can dramatically improve diagnostic efficiency and accuracy. For example, combining Philips IntelliSite with Ibex Medical Analytics’ AI software has demonstrated efficiency gains of 27% and productivity improvements of 37%.

Since 2013, Philips has helped more than 300 customers implement digital pathology in their laboratories, with over 20 hospital pathology labs transitioning to fully digital workflows, empowering pathologists to work seamlessly from anywhere in the world.